Psilocybin therapy, when paired with structured psychological support, showed early promise for improving mood and aspects of daily functioning in some people with Parkinson’s disease. Safety appeared acceptable within a carefully screened group. Because this was a small open label study with no control group, larger trials are required before clinical use can be recommended.